Table 5 Reporting assessment of included studies based on the CONSORT for Abstract checklist (n = 1385)

Title

1. Identification of the study as randomized

14 (1.01)

–

1371 (98.99)

Authors

2. Contact details for the corresponding author

234 (16.90)

1151 (83.10)

–

Trial design

3. Description of the trial design (e.g., parallel, cluster, non-inferiority)

1301 (93.34)

–

84 (6.66)

Participants

4. Eligibility criteria for participants and the settings where the data were collected

314 (22.67)

1071 (77.33)

Interventions

5.Interventions intended for each group

893 (64.48)

391 (28.23)

101 (7.29)

Objective

6.Specific objective or hypothesis

1374 (99.21)

–

11 (0.79)

Outcome

7.Clearly defined primary outcome for this report

0 (0)

761 (54.95)

624 (45.05)

Randomization

8.How participants were allocated to interventions

312 (22.53)

957 (69.10)

116 (8.38)

Blinding

9.Whether or not participants, caregivers, and those assessing the outcomes were blinded to group assignment

1 (0.07)

12 (0.87)

1372 (99.06)

Numbers randomized

10.Number of participants randomized to each group

1097 (79.21)

12 (0.87)

276 (19.93)

Recruiting objects

11.Clinical Trial Status

0 (0)

714 (51.55)

671 (48.45)

Numbers analyzed

12.Number of participants analyzed in each group

44 (3.18)

6 (0.43)

1335 (96.39)

Outcome

13.For the primary outcome, a result for each group and the estimated effect size and its precision

0 (0)

63 (4.55)

1322 (95.45)

Harms

14.Important adverse events or side effects

150 (10.83)

188 (13.57)

1047 (75.60)

Results

15.Generalized interpretation of outcome

1375 (99.28)

–

10 (0.72)

Trial registration

16.Registration number and name of trial register

0 (0)

1 (0.07)

1384 (99.93)

Funding

17.Source of funding

2 (0.14)

284 (20.51)

1100 (79.42)